Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer

Leonardo Mirandola, Yuefei Yu, Martin J. Cannon, Marjorie R. Jenkins, Rakhshanda L. Rahman, Diane D. Nguyen, Fabio Grizzi, Everardo Cobos, Jose A. Figueroa, Maurizio Chiriva-Internati

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective. Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3. Methods. We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested. Result. We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients. Conclusions. Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)573-579
Number of pages7
JournalGynecologic Oncology
Volume135
Issue number3
DOIs
StatePublished - Dec 1 2014

Fingerprint

Galectin 3
Drug Resistance
Ovarian Neoplasms
Galectins
Cell Line
Investigational Therapies
Growth
Cultured Cells
Pharmaceutical Preparations
Neoplasms

Keywords

  • Angiogenesis
  • Galectin-3
  • Galectin-3C
  • Invasion
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Medicine(all)

Cite this

Mirandola, L., Yu, Y., Cannon, M. J., Jenkins, M. R., Rahman, R. L., Nguyen, D. D., ... Chiriva-Internati, M. (2014). Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecologic Oncology, 135(3), 573-579. https://doi.org/10.1016/j.ygyno.2014.09.021

Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. / Mirandola, Leonardo; Yu, Yuefei; Cannon, Martin J.; Jenkins, Marjorie R.; Rahman, Rakhshanda L.; Nguyen, Diane D.; Grizzi, Fabio; Cobos, Everardo; Figueroa, Jose A.; Chiriva-Internati, Maurizio.

In: Gynecologic Oncology, Vol. 135, No. 3, 01.12.2014, p. 573-579.

Research output: Contribution to journalArticle

Mirandola, L, Yu, Y, Cannon, MJ, Jenkins, MR, Rahman, RL, Nguyen, DD, Grizzi, F, Cobos, E, Figueroa, JA & Chiriva-Internati, M 2014, 'Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer', Gynecologic Oncology, vol. 135, no. 3, pp. 573-579. https://doi.org/10.1016/j.ygyno.2014.09.021
Mirandola, Leonardo ; Yu, Yuefei ; Cannon, Martin J. ; Jenkins, Marjorie R. ; Rahman, Rakhshanda L. ; Nguyen, Diane D. ; Grizzi, Fabio ; Cobos, Everardo ; Figueroa, Jose A. ; Chiriva-Internati, Maurizio. / Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. In: Gynecologic Oncology. 2014 ; Vol. 135, No. 3. pp. 573-579.
@article{0540378d620848b89d612a79c10be926,
title = "Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer",
abstract = "Objective. Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3. Methods. We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested. Result. We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients. Conclusions. Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer.",
keywords = "Angiogenesis, Galectin-3, Galectin-3C, Invasion, Ovarian cancer",
author = "Leonardo Mirandola and Yuefei Yu and Cannon, {Martin J.} and Jenkins, {Marjorie R.} and Rahman, {Rakhshanda L.} and Nguyen, {Diane D.} and Fabio Grizzi and Everardo Cobos and Figueroa, {Jose A.} and Maurizio Chiriva-Internati",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.ygyno.2014.09.021",
language = "English (US)",
volume = "135",
pages = "573--579",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer

AU - Mirandola, Leonardo

AU - Yu, Yuefei

AU - Cannon, Martin J.

AU - Jenkins, Marjorie R.

AU - Rahman, Rakhshanda L.

AU - Nguyen, Diane D.

AU - Grizzi, Fabio

AU - Cobos, Everardo

AU - Figueroa, Jose A.

AU - Chiriva-Internati, Maurizio

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Objective. Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3. Methods. We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested. Result. We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients. Conclusions. Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer.

AB - Objective. Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3. Methods. We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested. Result. We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients. Conclusions. Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer.

KW - Angiogenesis

KW - Galectin-3

KW - Galectin-3C

KW - Invasion

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84920834833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920834833&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2014.09.021

DO - 10.1016/j.ygyno.2014.09.021

M3 - Article

C2 - 25284038

AN - SCOPUS:84920834833

VL - 135

SP - 573

EP - 579

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -